For this subgroup of patients, both granulocyte colony‐stimulating factor (GCSF) and 1‐palmitoyl‐2‐linoleoyl‐3‐acetyl‐rac‐glycerol (PLAG), a synthetic monoacetyldiglyceride, have shown potential clinical effectiveness in reducing GEM‐induced neutropenia.26 The gene discussed is CSF3; the disease is Decreased total neutrophil count.